Guardant Health Raises $360 Million in Race to Create Cancer Blood Tests
Guardant Health, a California-based biotechnology company that sells blood tests to track and detect cancer, recently announced a $360 million round of funding, which has been earmarked to support Guardant’s ambitious goal to test one million patients over the next five years. This massive amount of funding isn’t unheard of these days. Not long ago, Guardant’s fellow cancer detection startup GRAIL announced that it raised $900 million from big-name investors like Bristol-Myers Squibb and Johnson & Johnson. GRAIL also started its clinical trial of breast cancer...